Exelixisincis A Biopharmaceutical Company Founded In 1994 By A Team Of Scientistsincluding Corey Goodmanspyros Artavanis Tsakonasand Pamela Bjorkmanheadquartered In Alamedacaliforniaexelixis Is Dedicated To Developing Innovative Small Molecule Therapies For Cancer Treatmentthe Company Focuses On Discovering Drugs That Target Specific Pathways Involved In Cancer Formationgrowthand Metastasis Exelixis Markets Several Productsincluding Cometriqcabozantinib Approved For Medullary Thyroid Cancerand Cabometyxcabozantinib Which Is Used For Advanced Renal Cell Carcinoma And Hepatocellular Carcinomathe Company Is Also Advancing A Pipeline Of Promising Candidatessuch As Zanzalintinibxb002Xl102And Cbx 12Aimed At Treating Advanced Or Metastatic Solid Tumorsexelixis Collaborates With Other Biopharmaceutical Companies To Enhance Its Research And Commercialization Efforts
